AD drugs approved by the U.S. Food and Drug Administration (FDA), such as acetylcholine esterase inhibitors, only aim to improve mild-moderate AD patients’ symptoms (No authors listed, 2021). The gene discussed is ACHE; the disease is Alzheimer disease.